Navigation Links
Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer

RESEARCH TRIANGLE PARK, N.C., Jan. 3 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Neil Frazer, M.B., Ch.B., FRCA, FFPM has joined the company as Chief Medical Officer.

Prior to joining Chimerix, Dr. Frazer served as the Chief Medical Officer and Chief Operating Officer of Erimos Pharmaceuticals (previously Biocure Medical) where he was responsible for the design of clinical drug development programs to meet U.S. and global commercial, regulatory and scientific objectives. Prior to his tenure at Erimos, Dr. Frazer served as the Vice President, Clinical Research at Shire Pharmaceuticals where he was responsible for clinical drug development of key programs that included Adderall XR, Equetro and Fosrenol. Dr. Frazer has also held research and development positions at Pharmalink FHI, Medicab, Inc., TabSafe Medical Services, Inc., ClinTrials Research Inc. and Glaxo Wellcome, Inc. Dr. Frazer obtained his B.Sc. and medical degree from the University of Edinburgh Medical School.

"Dr. Frazer's years of research and development experience will be invaluable as we continue to advance our pipeline of orally available and topical antiviral agents through the clinical development process," said Dr. George Painter, Chimerix' President and CEO. "In addition to Dr. Frazer, we have also made a number of key hires in our research and development department, while maintaining our virtual research and development operating model to maintain maximum flexibility and cash efficiency."

With the addition of the new staff, Chimerix currently has 16 full-time employees. To accommodate the new employees, Chimerix has moved its headquarters to 2505 Meridian Parkway, Durham, NC 27713.

About Chimerix

Chimerix, Inc. discovers, develops and commercializes therapeutics with enhanced pharmaceutical properties that are active against a broad range of viral diseases. Leveraging a powerful lipid, prodrug technology, ProLipTag(TM), Chimerix is able to develop drug candidates with oral-availability, increased potency and targeted delivery. These enhanced pharmaceutical properties can be applied to new drug moieties or known drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse events.

SOURCE Chimerix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
2. Codexis Appoints Singapore Laboratories Managing Director
3. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
4. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
5. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
6. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
7. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
8. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
9. NeurogesX Appoints New Director to the Board
10. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
11. Premier Research Appoints Melissa Jones as Vice President, International Business Development
Post Your Comments:
(Date:10/10/2017)... International research firm Parks Associates announced today that ... TMA 2017 Annual Meeting , October 11 in Scottsdale, ... security market and how smart safety and security products impact the competitive ... Parks Associates: Smart Home Devices: Main ... "The residential security market has experienced continued ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... , ... At its national board meeting in North Carolina, ARCS® Foundation ... of Physics and Astronomy, has been selected for membership in ARCS Alumni Hall ... 2015 Breakthrough Prize in Fundamental physics for the discovery of the accelerating expansion of ...
Breaking Biology Technology:
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
Breaking Biology News(10 mins):